Skip to Content
Merck
CN

Molecular optical imaging with radioactive probes.

PloS one (2010-03-09)
Hongguang Liu, Gang Ren, Zheng Miao, Xiaofen Zhang, Xiaodong Tang, Peizhen Han, Sanjiv S Gambhir, Zhen Cheng
ABSTRACT

Optical imaging (OI) techniques such as bioluminescence and fluorescence imaging have been widely used to track diseases in a non-invasive manner within living subjects. These techniques generally require bioluminescent and fluorescent probes. Here we demonstrate the feasibility of using radioactive probes for in vivo molecular OI. By taking the advantages of low energy window of light (1.2-3.1 eV, 400-1000 nm) resulting from radiation, radionuclides that emit charged particles such as beta(+) and beta(-) can be successfully imaged with an OI instrument. In vivo optical images can be obtained for several radioactive probes including 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG), Na(18)F, Na(131)I, (90)YCl(3) and a (90)Y labeled peptide that specifically target tumors. These studies demonstrate generalizability of radioactive OI technique. It provides a new molecular imaging strategy and will likely have significant impact on both small animal and clinical imaging.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Yttrium(III) chloride hexahydrate, 99.999% trace metals basis
Sigma-Aldrich
Yttrium(III) chloride hexahydrate, 99.99% trace metals basis
Sigma-Aldrich
Yttrium(III) chloride hexahydrate, 99.9% trace metals basis
Sigma-Aldrich
Yttrium(III) chloride, anhydrous, powder, 99.99% trace metals basis
Sigma-Aldrich
Yttrium(III) chloride, AnhydroBeads, −10 mesh, 99.99% trace metals basis